ReviewTobacco control2022
Moving targets: how the rapidly changing tobacco and nicotine landscape creates advertising and promotion policy challenges.
Review in Tobacco control, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Prevalence and determinants of e-cigarette use in South Asia: a systematic review.BMJ global health · 2025Pooled it
- Appeal and Sensory Characteristics of Oral Nicotine Products in Young Adults Who Vape E-Cigarettes.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2026Trial
- Nicotine Pouch Advertising and Sales in Australia: A Qualitative Study of Younger People's Experiences.Health promotion journal of Australia : official journal of Australian Association of Health Promotion Professionals · 2026Article
- Neuropharmacology of Nicotine Addiction and Therapeutic Strategies for Smoking Cessation.Biology · 2026Review
- Investigation of Differences in Tobacco Use Language Between Groups: Corpus-Assisted Analysis.JMIR infodemiology · 2026Article
- Narrative Review of Novel Nicotine-Delivery Systems and Emerging Pharmaceuticals for Tobacco Cessation.Medicines (Basel, Switzerland) · 2026Review
- The policy implementation playbook: a cross-policy taxonomy of post-adoption tobacco industry tactics.Globalization and health · 2026Review
- From awareness to action: building monitoring capacity for tobacco and nicotine industry interference-experience from the JA PreventNCD project.European journal of public health · 2026Article
- Consumption of four unhealthy commodities and exposure to advertising, sponsorship, and promotion in Bamako, Mali.Health promotion international · 2026Article
- Consumer Characteristics, Tobacco Control Policies, and Disparities in Discontinued Cigarette Purchases: Evidence from U.S. Households (2010-2021).Substance use & addiction journal · 2026Article
- Australia's proposed gambling reforms may be good for industry, but not for public health.Health promotion international · 2026Article
- Tobacco control policies discussed on social media: a scoping review.Tobacco control · 2026Article
- An Exploratory Typology of Tobacco-Related Misleading Content on Social Media: Qualitative Analysis of Instagram and TikTok.Journal of medical Internet research · 2025Article
- Article
- Building an analytical framework for tobacco-related information on social media: an exploratory analysis with generative AI assistance.BMC public health · 2025Article
- The Health Effects of Heated Tobacco Product Use-A Narrative Review.Healthcare (Basel, Switzerland) · 2025Review
- Remediated marketing: leveraging computer vision and rule-based classification models to detect e-cigarette warning labels across social media.Information, communication and society · 2025Article
- The impact of e-cigarette product characteristics on attitudes and use susceptibility: an experimental study.Health promotion international · 2025Article
- The Potential Impact of Oral Nicotine Pouches on Public Health: A Scoping Review.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2025Article
- Trends in type 2 diabetes-related deaths and disability-adjusted life years among smoking middle-aged and elderly adults in China, 1990-2021.Tobacco induced diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 4 countries.
Funding
Abstract
Tobacco, nicotine and related products have and continue to change rapidly, creating new challenges for policies regulating their advertising, promotion, sponsorship and sales. This paper reviews recent commercial product offerings and the regulatory challenges associated with them. This includes electronic nicotine delivery systems, electronic non-nicotine delivery systems, personal vaporisers, heated tobacco products, nicotine salts, tobacco-free nicotine products, other nicotine products resembling nicotine replacement therapies, and various vitamin and cannabis products that share delivery devices or marketing channels with tobacco products. There is substantial variation in the availability of these tobacco, nicotine, vaporised, and related products globally, and policies regulating these products also vary substantially between countries. Many of these products avoid regulation by exploiting loopholes in the definition of tobacco or nicotine products, or by occupying a regulatory grey area where authority is unclear. These challenges will increase as the tobacco industry continues to diversify its product portfolio, and weaponises 'tobacco harm reduction' rhetoric to undermine policies limiting marketing, promotion and taxation of tobacco, nicotine and related products. Tobacco control policy often lags behind the evolution of the industry, which may continue to sell these products for years while regulations are established, refined or enforced. Policies that anticipate commercial tobacco, nicotine and related product and marketing changes and that are broad enough to cover these product developments are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.